SOLIGENIX, INC. (SNGX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US8342236044
SOLIGENIX, INC. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -11.85 m USD |
| EBIT | -11.59 m USD |
| Net income | -11.08 m USD |
| Diluted EPS – continuing operations | -2.14 USD |
Full history since 1995, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About SOLIGENIX, INC.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
More stocks
- XERIANT, INC. (XERI)
- Bridgeline Digital, Inc. (BLIN)
- Curanex Pharmaceuticals Inc (CURX)
- BTC Digital Ltd. (BTCT)
- Vynleads, Inc. (VYND)
- BARFRESH FOOD GROUP INC. (BRFH)
- Next Meats Holdings, Inc. (NXMH)
- KBS Real Estate Investment Trust III, Inc. (KBSR)
- DevvStream Corp. (DEVSF)
- EQUUS TOTAL RETURN, INC. (EQS)
- LSEB Creative Corp. (LSEB)
- Cycurion, Inc. (CYCU)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.